Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023597 | 0.82 | ALDH1A1 (0.32) | ALDH1A1CYP19A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18389694 | 0.82 | POLB (0.34) | ALDH1A1CYP19A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10028023 | 0.81 | CARM1 (0.36) | ALDH1A1CYP19A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22825220 | 0.81 | CYP2C19 (0.36) | ALDH1A1CYP19A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19981934 | 0.80 | — | — | |
| SCHEMBL14589097 | 0.80 | CYP19A1 (0.39) | ALDH1A1CYP19A1PIK3CDMEN1KMT2A | |
| SCHEMBL18885707 | 0.78 | LMNA (0.40) | ALDH1A1 | |
| SCHEMBL13071687 | 0.78 | CYP19A1 (0.35) | ALDH1A1CYP19A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23948519 | 0.77 | LMNA (0.41) | ALDH1A1CYP19A1PIK3CDMEN1KMT2A | |
| SCHEMBL19013129 | 0.77 | FOLH1 (0.36) | ALDH1A1CYP19A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793885-B2 | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders | IMMUNOGEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220202947-A1 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | IMMUNOGEN, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210147560-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3313884-B9 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10919969-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10875925-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200397914-A1 | BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20180079819-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202947-A1 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | BHMT2, MGMT, MTR | ALDH1A1 211/4885CYP19A1 3268/4885PIK3CD 4842/4885 |
| US-20180079819-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | ALDH1A1 1167/4885CYP19A1 4409/4885PIK3CD 3762/4885 |
| US-20210147560-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IL23R, CD22, IL2RA | ALDH1A1 1167/4885CYP19A1 4409/4885PIK3CD 3762/4885 |
| US-10875925-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | ALDH1A1 1167/4885CYP19A1 4409/4885PIK3CD 3762/4885 |
| US-20200397914-A1 | BENZODIAZEPINE DERIVATIVES | GABRA5, GABRA3, GABRA1 | ALDH1A1 751/4885CYP19A1 360/4885PIK3CD 2453/4885 |
| US-10919969-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | ALDH1A1 1167/4885CYP19A1 4409/4885PIK3CD 3762/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | ALDH1A1 1167/4885CYP19A1 4409/4885PIK3CD 3762/4885 |
| US-11793885-B2 | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders | MKI67, GABBR1, GABBR2 | ALDH1A1 540/4885CYP19A1 240/4885PIK3CD 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.